Patents by Inventor Helen KOTANIDES

Helen KOTANIDES has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMANIZED ANTI-CD45 ANTIBODIES
    Publication number: 20240010744
    Abstract: Provided are humanized anti-human CD45 antibodies and pharmaceutical compositions including the antibodies.
    Type: Application
    Filed: September 11, 2023
    Publication date: January 11, 2024
    Inventors: Lequn ZHAO, Helen KOTANIDES
  • CALRETICULIN NANOBODIES
    Publication number: 20230416348
    Abstract: Provided are nanobodies that bind human calreticulin, fusion proteins including the nanobodies, pharmaceutical compositions including the nanobodies or fusion proteins, and radioconjugates of the nanobodies or fusion proteins.
    Type: Application
    Filed: May 24, 2023
    Publication date: December 28, 2023
    Inventors: GHOLAMREZA HASSANZADEH GHASSABEH, STEVE SCHOONOOGHE, HELEN KOTANIDES
  • ANTI-CD137 ANTIBODIES
    Publication number: 20230279134
    Abstract: The present invention relates to antibodies that bind to human CD137 and display agonist activity, and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.
    Type: Application
    Filed: November 1, 2022
    Publication date: September 7, 2023
    Inventors: Christopher Carl FRYE, Michael Dewain KALOS, Helen KOTANIDES, Stephanie Lynn SANDEFUR
  • Anti-CD137 antibodies
    Patent number: 11512134
    Abstract: The present invention relates to antibodies that bind to human CD137 and display agonist activity, and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.
    Type: Grant
    Filed: January 23, 2020
    Date of Patent: November 29, 2022
    Assignee: ELI LILLY AND COMPANY
    Inventors: Christopher Carl Frye, Michael Dewain Kalos, Helen Kotanides, Stephanie Lynn Sandefur
  • Anti-CD137 antibodies
    Patent number: 10906983
    Abstract: The present invention relates to antibodies that bind to human CD137 and display agonist activity, and is useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: February 2, 2021
    Assignee: ELI LILLY AND COMPANY
    Inventors: Christopher Carl Frye, Michael Dewain Kalos, Helen Kotanides, Stephanie Lynn Sandefur
  • ANTI-CD137 ANTIBODIES
    Publication number: 20200377607
    Abstract: The present invention relates to antibodies that bind to human CD137 and display agonist activity, and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.
    Type: Application
    Filed: July 25, 2018
    Publication date: December 3, 2020
    Inventors: Christopher Carl FRYE, Michael Dewain KALOS, Helen KOTANIDES, Stephanie Lynn SANDEFUR
  • ANTI-CD137 ANTIBODIES
    Publication number: 20200157234
    Abstract: The present invention relates to antibodies that bind to human CD137 and display agonist activity, and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.
    Type: Application
    Filed: January 23, 2020
    Publication date: May 21, 2020
    Inventors: Christopher Carl FRYE, Michael Dewain KALOS, Helen KOTANIDES, Stephanie Lynn SANDEFUR